Sofar

Trezzano Rosa, Italy Founded: 1968 • Age: 58 yrs Acquired By Fine Foods and Pharmaceuticals NTM
Pharmaceutical finished products such as tablets and capsules are manufactured.

About Sofar

Sofar is a Healthcare company based in Trezzano Rosa (Italy) founded in 1968, and was acquired by Fine Foods and Pharmaceuticals NTM in April 2026. Pharmaceutical finished products such as tablets and capsules are manufactured. It operates on a Professional Services model. Its chief executive, as recorded, is Andrea Biffi. Sofar offers products and services including Pharmaceutical Production. Its focus areas include Pharmaceuticals and Manufacturing. Its legal entity is Sofar S.p.A.

Company details

Sofar S.p.A. is focused on pharmaceutical production and operates as a Contract Development and Manufacturing Organization (CDMO). The commercial branch of Sofar S.p.A. was transferred to Alfasigma S.p.A. as of February 1, 2023. The company continues to serve the healthcare sector by providing manufacturing solutions and maintaining compliance with legal and data protection regulations.

  • Headquarters Trezzano Rosa, Italy
  • Stage Acquired
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website sofarfarm.it
  • Social LinkedIn
  • Acquired by Alfasigma (Aug 2022)
  • Legal Name Sofar S.P.A.
Key Metrics

Products & Services of Sofar

Sofar offers a comprehensive portfolio of products and services, including Pharmaceutical Production.

Pharmaceutical Production
Manufacturing

Pharmaceutical products are manufactured for health sector needs.

Funding Insights of Sofar

  • Total Rounds 1
  • Last Round Unspecified β€” $52,350
  • First Round $52,350

    (May 2019)

All 1 funding rounds of Sofar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2019$52,350Unspecified––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Sofar

Sofar has secured backing from 2 investors. Prominent investors backing the company include Alfasigma and Fine Foods and Pharmaceuticals NTM.

All
InvestorDescriptionFounded YearDomainLocation
Generic tablets, capsules, syrups, and injectables are manufactured.
2015alfasigma.comBologna, Italy
Pharmaceuticals and nutraceuticals are developed and manufactured under contract.
1985finefoods.itBergamo, Italy
Premium access

Investor details for Sofar

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Sofar

1 people are tracked at Sofar (1 in leadership).

NameRoleGroup
Andrea Biffi
CEOLeadership
Premium access

Complete people profiles for Sofar

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Sofar

4 dated milestones of Sofar across 58 years, from founding to its latest funding, stage changes and deals.

  1. Founded Sofar is founded.
  2. Funding First funding round of $52K.
  3. Exit Acquired by Alfasigma.
  4. Exit Acquired by Fine Foods and Pharmaceuticals NTM.

Web traffic of Sofar

The website of Sofar (sofarfarm.it) receives about 1.2K visits a month.

  • Monthly visits
    1.2K

    ▲ 21.1% vs previous month

Similar websites

Websites whose visitors overlap most with Sofar. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pharmaciaitalia.it
pharmaciaitalia.it
100%
–
errekappa.it
82%
#4,544,748View details
pfizer.it
pfizer.it
79%
#2,175,497–
cadigroup.it
cadigroup.it
74%
#5,483,804–
anticafarmacia.it
anticafarmacia.it
74%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for Sofar

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sofar

Premium access

Complete news archive for Sofar

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sofar

Sofar was founded in 1968 and raised its 1st funding round 51 years after it was founded.

Sofar is headquartered in Trezzano Rosa, Italy. It is registered at Trezzano Rosa, Lombardy, Italy.

Andrea Biffi is the CEO of Sofar, as recorded in our data.

Sofar S.p.A. is focused on pharmaceutical production and operates as a Contract Development and Manufacturing Organization (CDMO). The commercial branch of Sofar S.p.A. was transferred to Alfasigma S.p.A. as of February 1, 2023. The company continues to serve the healthcare sector by providing manufacturing solutions and maintaining compliance with legal and data protection regulations.

Sofar offers Pharmaceutical Production.

Sofar has 2 investors. Key investors include Alfasigma, and Fine Foods and Pharmaceuticals NTM.

Sofar operates through Sofar S.P.A..

Yes. Sofar was acquired by Alfasigma in August 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available